Trial Profile

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NV-5138 (Primary)
Indications Major depressive disorder
Focus Therapeutic Use
Sponsors Navitor Pharmaceuticals

Most Recent Events

21 May 2025 Status changed from recruiting to completed.
18 Feb 2025 Primary endpoint (Evaluation of the efficacy of NV-5138 as measured by the Montgomery-Asberg Depression Rating scale) has not been met, according to Supernus Pharmaceuticals Media Release.
18 Feb 2025 Top-line results presented in a Supernus Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com